C1Q NEPHROPATHY: A MULTIFACETED DISEASE WITH INFREQUENT DIAGNOSIS

Authors

  • Naima Tariq
  • Humaira Nasir Consultant Histopathologist. Shifa International Hospital.
  • Tahir Aziz Ahmed Consultant Pathology and Immunology. Shifa International Hospital.
  • Mariam Usman Shifa International Hospital
  • Khawaja Sayeed Ahmed Shifa International Hospital

Abstract

Background: C1q nephropathy (C1qN) is a rare glomerulopathy, with a very low prevalence world wide varying from 0.2 to 2.5%. Even though more than three decades have passed since this entity was first explained, still, it remains a dilemma for many due to the rarity of this lesion. This study was carried out principally to determine the clinical presentation, morphologic features and distribution of C1qN in our region based on renal biopsies studied by light microscopy (LM), and immunofluorescence (IF) so that this entity is better understood both by nephrologists and pathologists as no such study has ever been conducted in Pakistan to our knowledge. Methods: It was a cross-sectional study carried out from 1st January 2012 to 30th December 2016 in Histopathology department, Shifa International Hospital. All cases diagnosed as C1q nephropathy were retrieved from the hospital’s computerized database. Their clinical profiles, morphology and immunohistochemical profiles were studied. Results: Over this period a total of 31 cases were diagnosed with C1qN. Mean age of the patients was 32.09±18.66 years. The most common clinical presentation was nephrotic syndrome seen in 22 (71%) patients. The most frequent morphological pattern seen was minimal change disease (MCD) in 13 (41.9%) cases. All cases showed dominant 22 (71%) or codominant 9 (42.9%) mesangial±membranous C1q deposition. No correlation was found (p-value >0.05) between morphological pattern and clinical presentation of the disease or immunofluorescence findings. Conclusion: C1qN is a rare entity which is primarily diagnosed on the basis of immunofluorescence findings with a dominant or codominant fluorescent intensity for C1q. It is recommended that C1qN is sought for preferably with immunofluorescence staining of biopsies for immune reactants, especially for C1q. Studies from this part of the world are strongly recommended to predict clinical outcome and treatment options.Keywords: C1q nephropathy; immunofluorescence; immune reactants; histopathological patterns

Author Biographies

Humaira Nasir, Consultant Histopathologist. Shifa International Hospital.

Consultant Hstopathologist.Shifa International Hospital.

Tahir Aziz Ahmed, Consultant Pathology and Immunology. Shifa International Hospital.

Consultant Pathology and Immunology.Shifa International Hospital.

Mariam Usman, Shifa International Hospital

Resident HistopathologyShifa International Hospital

Khawaja Sayeed Ahmed, Shifa International Hospital

Consultant NephrologistShifa International Hospital.

References

Iskandar SS, Browning MC, Lorentz WB. C1q nephropathy: a pediatric clinicopathologic study. Am J Kidney Dis 1991;18(4):459–65.

Markowitz GS, Schwimmer JA, Stokes MB, Nasr S, Seigle RL, Valeri AM, et al. C1q nephropathy: a variant of focal segmental glomerulosclerosis. Kidney Int 2003;64(4);1232–40.

Lau KK, Gaber LW, Santos NMD, Wyatt RJ. C1q nephropathy: features at presentation and outcome. Pediatr Nephrol 2005;20(6):744–9.

Jennette JC, Hipp CG. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis 1985;6(2):103–10.

Lu JH, Teh BK, Wang LD, Wang YN, Tan YS, Lai MC, et al. The classical and regulatory functions of C1q in immunity and autoimmunity. Cell Mol Immunol 2008;5(1):9–21.

Devasahayam J, Erode-Singaravelu G, Bhat Z, Oliver T, Chandran A, Zeng X, et al. C1q nephropathy: the unique underrecognized pathological entity. An Cell Pathol (Amst) 2015;2015:490413.

Malleshappa P, Vankalakunti M. Diverse clinical and histology presentation in C1q nephropathy. Nephro Urol Mon 2013;5(3):787–91.

Gunasekara VN, Sebire NJ, Tullus K. C1q nephropathy in children: clinical characteristics and outcome. Pediatr Nephrol 2014;29(3):407–13.

Hisano S, Fukuma Y, Segawa Y, Niimi K, Kaku Y, Hatae K, et al. Clinicopathologic correlation and outcome of C1q nephropathy. Clin J Am Soc Nephrol 2008;3(6):1637–43.

Vizjak A, Ferluga D, Rozic M, Hvala A, Lindic J, Levart TK, et al. Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol 2008;19(11):2237–44.

Wenderfer SE, Swinford RD, Braun MC. C1q nephropathy in the pediatric population: pathology and pathogenesis. Pediatr Nephrol 2010;25(8):1385–96.

Schrier RW. Renal and electrolyte disorders. Baltimore: Lippincott Williams & Wilkins, 2010; p.560.

Rovin BH. Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults. [Internet]. UpToDate 2018. [cited 2018 Nov 22]. Available from: https://www.uptodate.com/contents/assessment-of-urinary-protein-excretion-and-evaluation-of-isolated-non-nephrotic-proteinuria-in-adults.

Kanodia KV, Vanikar AV, Patel RD, Suthar KS, Patel HV, Gumber MA, et al. C1q nephropathy in India: a single-center study. Saudi J Kidney Dis Transpl 2015;26(2):398–403.

Wong CS, Fink CA, Baechle J, Harris AA, Staples AO, Brandt JR. C1q nephropathy and minimal change nephrotic syndrome. Pediatr Nephrol 2009;24(4):761–7.

Malleshappa P. C1q nephropathy- unity in diversity. J Renal Inj Prev 2013;2(4):117–8.

Mokhtar GA, Jalalah SM. A clinicopathological study of C1q nephropathy at King Abdulaziz University. Iran J Kidney Dis 2015;9(4):279–85.

Kari JA, Jalalah SM. C1q nephropathy in two young sisters. Pediatr Nephrol 2008;23(3):487–90.

Abu-Shahin N, Al-Khader A, Qattan D, Akl K. C1q nephropathy among children with nephrotic syndrome: Ten-year experience from a pediatric nephrology unit. Turk J Pediatr 2018;60(1):14–21.

Kanai T, Akioka Y, Miura K, Hisano M, Koike J, Yamaguchi Y, et al. Predominant but silent C1q deposits in mesangium on transplanted kidneys - long-term observational study. BMC Nephrol 2018;19(1):82.

Apr 6;19(1):82.

Published

2019-08-07